Hybrid Core-Shell Particles for Systemic mRNA Delivery

Study Background and Research Question

In vitro transcribed mRNA can produce protein without entering the nucleus, making it attractive for vaccination, cancer immunotherapy, gene editing, cellular reprogramming, and transient protein replacement. The central engineering problem is not only to protect mRNA from degradation, but also to control where a formulation travels after administration and where the encoded protein is translated. This challenge becomes especially important for systemic delivery, where particle stability, surface charge, tissue distribution, cellular uptake, endosomal escape, and innate sensing are interdependent.

The study Hybrid core-shell particles for mRNA systemic delivery addressed this problem by investigating hyaluronic acid as a surface coating for liposome–mRNA complexes. According to the reference study, the researchers asked whether a polymer shell could modify the physicochemical properties of positively charged liposome–mRNA complexes without eliminating their biological activity. They also examined whether changes in particle surface characteristics would alter biodistribution and the anatomical sites of protein production.

Key Innovation from the Reference Study

The core innovation was a hybrid architecture rather than a completely new carrier class. First, mRNA was complexed with liposomes to form positively charged liposome–mRNA complexes, or LRCs. Hyaluronic acid was then electrostatically associated with these complexes, producing hyaluronic acid-coated hybrid LRCs, or HLRCs. This design places the nucleic acid payload within a lipid-based core while using the outer polymer layer to tune the interface between the particle and biological fluids.

This arrangement is scientifically useful because surface charge is a major determinant of colloidal behavior and cell interactions. Positive particles can interact efficiently with negatively charged nucleic acids and cell membranes, but excessive positive charge may also affect serum stability, nonspecific interactions, and tolerability. The HA shell shifted the surface from positive to negative while maintaining a particle size and mRNA-binding profile similar to the uncoated formulation. The paper reports particle sizes of approximately 200 nm for the formulations examined, although the most important result was the preservation of functional delivery despite the charge reversal.

The innovation should therefore be interpreted as a modular formulation strategy. It does not claim that HA alone creates cell-specific targeting. Instead, it demonstrates that a core–shell structure can fine-tune nanoparticle properties and create a platform for subsequent optimization of systemic mRNA delivery.

Methods and Experimental Design Insights

The experimental design connected formulation chemistry with biological performance at several levels. The investigators prepared LRCs and HLRCs at different nitrogen-to-phosphate ratios, commonly expressed as N/P ratios. This comparison allowed them to examine how the amount of cationic lipid relative to the phosphate groups of mRNA affected complex formation and particle characteristics. They then evaluated particle size, surface charge, and mRNA-binding ability to determine whether HA coating changed the physical organization of the complexes.

Biological testing included both a monocytic cell line and primary human cells. THP-1 cells provided a reproducible model for screening transfection, while human monocytes derived from peripheral blood mononuclear cells offered a more physiologically relevant immune-cell context. This pairing is important for studies focused on macrophage or monocyte delivery because a formulation can perform well in an immortalized line yet behave differently in primary cells.

The in vivo design used two complementary measurements. Radiolabeled LRC and HLRC particles were used for quantitative biodistribution, providing information about where the carrier-associated signal accumulated. In parallel, bioluminescence measurements were used to identify sites where translated protein was produced. These readouts answer different questions: radiolabeling tracks particle-associated material, whereas reporter expression reflects successful intracellular delivery and translation. The distinction prevents a common interpretive error in which organ accumulation is treated as equivalent to productive mRNA expression.

Protocol Parameters

The following parameters summarize the reference study. They should be treated as literature-derived design considerations rather than a universal formulation protocol.

• Core formulation: Assemble positively charged liposome–mRNA complexes before applying the hyaluronic acid shell; the coating is formed through electrostatic association with the preformed complexes, as described in the reference study.
• N/P-ratio screening: Compare multiple N/P conditions rather than assuming that one ratio will optimize size, mRNA binding, and transfection simultaneously.
• Particle characterization: Measure size, surface charge, and mRNA association for both LRCs and HLRCs; the reported particles were approximately 200 nm, with HA changing the surface charge from positive to negative.
• In vitro models: Evaluate both THP-1 cells and primary human monocytes from peripheral blood mononuclear cells when the intended application concerns monocyte or macrophage biology.
• In vivo interpretation: Pair a carrier-distribution measurement with a translation reporter whenever possible, because organ accumulation and productive protein expression may occur at different sites.

For a new formulation, these parameters support a staged workflow: first confirm complex formation and colloidal properties, then quantify reporter expression in relevant cells, and finally compare biodistribution with translation. The paper does not provide evidence that every HA-coated formulation will show the same behavior, so polymer characteristics, lipid composition, administration conditions, and mRNA sequence remain variables requiring independent optimization.

Core Findings and Why They Matter

The first major finding was that HA coating produced a clear surface-charge change without a large change in the overall physical profile of the particles. LRCs were positively charged, whereas HLRCs acquired a negative surface charge. Nevertheless, the two particle sets showed similar size and mRNA-binding behavior across the tested formulation space, according to the study data. This result supports the idea that surface chemistry can be modified independently of some core properties.

The second finding was strong in vitro transfection in both THP-1 cells and human monocytes. For researchers developing mRNA delivery for gene expression in immune-cell models, this is a meaningful result because primary monocytes are more relevant than a single transformed cell line for several immunology and oncology applications. At the same time, high expression in vitro should not be equated with selective systemic delivery in vivo.

The in vivo results provided the most important biological insight. Both LRCs and HLRCs showed accumulation in the hepatic reticuloendothelial system, while translated protein was detected mainly in the spleen, with a preference for macrophages. This separation between carrier distribution and expression site suggests that the tissue receiving the largest particle-associated signal is not necessarily the tissue with the greatest functional delivery. Intracellular uptake, release of mRNA, and translation can reshape the final expression pattern.

These findings also clarify the scope of the work. The study demonstrates tunable physicochemical properties and effective reporter expression, but it does not establish disease-specific targeting or therapeutic benefit. Nor does it directly prove suppression of RNA-mediated innate immune activation. Reduced innate sensing may be an objective in the broader design of modified mRNA formulations, but it requires dedicated cytokine, interferon, or innate-response assays rather than inference from surface charge or protein expression alone.

Comparison with Existing Internal Articles

The reference paper complements the internal article Charge-Reversed Exosomes Enable Targeted mRNA Delivery to Cartilage. Both studies treat surface-charge engineering as a way to address biological barriers, but their goals differ. The Andretto study examines systemic distribution and immune-cell expression with hybrid liposome–polymer particles, whereas the exosome work focuses on penetration of cartilage and delivery to chondrocytes. The comparison is useful for formulation reasoning, not as evidence that one carrier can be transferred directly into the other tissue setting.

For reporter-based method development, Optimizing Reporter Assays with EZ Cap™ EGFP mRNA (5-moUTP) provides a complementary perspective on standardizing expression readouts. Its focus is assay workflow and reporter reproducibility, while the reference study contributes the carrier-design and biodistribution framework. Together, they emphasize that reporter signal depends on both the mRNA construct and the delivery system used to transport it.

Why this cross-domain matters, maturity, and limitations

Comparing systemic immune-cell delivery with cartilage delivery highlights a general principle: charge engineering is context-dependent. A surface that improves colloidal stability or tissue penetration in one biological environment may alter protein adsorption, uptake, or clearance in another. The evidence is therefore mature enough to support comparative formulation studies, but not to justify assuming that HA-coated liposome–mRNA complexes will target cartilage, tumors, or a particular immune-cell subset without new experiments.

Limitations and Transferability

Several limitations should guide interpretation. First, radiolabeled biodistribution indicates where particle-associated material is detected, but it does not by itself establish whether intact nanoparticles, free mRNA, degraded label, or metabolites account for the signal. The paired bioluminescence experiment improves interpretation, yet reporter expression still does not identify every intracellular step responsible for delivery.

Second, the in vitro models emphasize monocytes and macrophage-related biology. They do not represent endothelial cells, hepatocytes, stromal cells, or disease-specific tissue barriers. The mouse findings are valuable for formulation development, but species differences in immune recognition, HA interactions, clearance, and splenic organization may affect translation to human studies.

Third, the study primarily establishes a platform and a distribution-expression relationship. It does not define a universal HA molecular-weight requirement, coating density, optimal dose, repeat-administration schedule, therapeutic mRNA sequence, or long-term safety profile. Those variables should be measured in follow-up work. A fluorescence-based translation efficiency assay or an in vivo imaging with fluorescent mRNA workflow can help compare constructs, but fluorescence must still be interpreted alongside particle characterization and tissue-level biology.

Research Support Resources

For researchers establishing comparable reporter and delivery workflows, EZ Cap™ EGFP mRNA (5-moUTP) (SKU R1016) is an enhanced green fluorescent protein mRNA reference containing a Cap1 analog, 5-methoxyuridine-modified nucleotides, and an optimized poly(A) tail. The product information reports a 996-nucleotide transcript supplied at 1 mg/mL; these specifications should be checked against the current product page before planning experiments. It can support reporter-based mRNA delivery, translation efficiency assay development, and imaging-oriented studies, but it does not replace optimization of the carrier, cell model, or biodistribution measurements. For handling, the product information recommends RNase-controlled conditions, storage at −40 °C or below, aliquoting to limit freeze–thaw cycles, and mixing with transfection reagent before addition to serum-containing medium.